🟢 Telix Pharmaceuticals is trading 4.2% up today on strong Q2 revenue growth and pipeline progress

Telix Pharmaceuticals is trading at $10.95, up 4.2% today, after investors digested a strong quarterly performance and clinical pipeline update.

• The company reported a 21% jump in Q2 2026 revenue, reflecting significant commercial momentum.
• Management highlighted key advancements across its clinical pipeline and strategic partnerships.
• The positive update appears to be supporting investor sentiment despite a relatively cautious environment in the broader markets.